清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

医学 克拉斯 内科学 曲妥珠单抗 表皮生长因子受体 肿瘤科 实体瘤疗效评价标准 癌症 结直肠癌 胃肠病学 临床研究阶段 毒性 乳腺癌
作者
Masataka Yagisawa,Hiroya Taniguchi,Taroh Satoh,Shigenori Kadowaki,Yu Sunakawa,Tomohiro Nishina,Yoshito Komatsu,Taito Esaki,Daisuke Sakai,Ayako Doi,Takeshi Kajiwara,Hiromi Ono,Masatoshi Asano,Nami Hirano,Justin I. Odegaard,Satoshi Fujii,Shogo Nomura,Hideaki Bando,Akihiro Sato,Takayuki Yoshino,Yoshiaki Nakamura
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
标识
DOI:10.1200/jco.23.02626
摘要

PURPOSE HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 ( HER2)–amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-amplified solid tumors determined with cfDNA testing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开拖拉机的医学僧完成签到 ,获得积分10
3秒前
123完成签到 ,获得积分10
7秒前
danli完成签到 ,获得积分10
13秒前
krathhong完成签到 ,获得积分10
14秒前
数乱了梨花完成签到 ,获得积分10
17秒前
20秒前
27秒前
28秒前
Gary完成签到 ,获得积分10
30秒前
彪壮的狗发布了新的文献求助10
33秒前
44秒前
48秒前
俏皮诺言完成签到 ,获得积分10
48秒前
49秒前
勤恳依霜发布了新的文献求助10
53秒前
SciGPT应助勤恳依霜采纳,获得10
1分钟前
洒家完成签到 ,获得积分10
1分钟前
ljssll完成签到 ,获得积分10
1分钟前
zhdjj完成签到 ,获得积分10
1分钟前
浮云完成签到 ,获得积分10
1分钟前
yn完成签到 ,获得积分10
1分钟前
Nancy发布了新的文献求助10
1分钟前
HCCha完成签到,获得积分10
1分钟前
Singularity举报顺顺欣求助涉嫌违规
1分钟前
zcydbttj2011完成签到 ,获得积分10
1分钟前
Nancy发布了新的文献求助10
2分钟前
川藏客完成签到 ,获得积分10
2分钟前
小强完成签到 ,获得积分10
2分钟前
Hairmon完成签到 ,获得积分10
3分钟前
3分钟前
不配.应助滕皓轩采纳,获得10
3分钟前
3分钟前
3分钟前
庆次完成签到 ,获得积分10
3分钟前
spring完成签到 ,获得积分0
3分钟前
Shao_Jq完成签到 ,获得积分10
4分钟前
Hiaoliem完成签到 ,获得积分10
4分钟前
zz完成签到 ,获得积分10
4分钟前
我是笨蛋完成签到,获得积分10
4分钟前
wt关闭了wt文献求助
4分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099800
求助须知:如何正确求助?哪些是违规求助? 2751277
关于积分的说明 7612141
捐赠科研通 2403037
什么是DOI,文献DOI怎么找? 1275146
科研通“疑难数据库(出版商)”最低求助积分说明 616276
版权声明 599053